Acorda Therapeutics, Inc.: Nasdaq/NYSE listing notice — Acorda Therapeutics faces Nasdaq delisting for bid price noncompliance; hearing requested

Acorda Therapeutics, Inc.

Nasdaq notified Acorda that common stock will be delisted on Dec 29, 2022 for failing to maintain $1 minimum bid price for 30 consecutive business days.
Company had 180-day compliance period that ended Dec 19, 2022; did not regain compliance.
Acorda will request a hearing within 7 days, which automatically stays delisting pending Panel decision.
Hearings Panel may grant extension to regain compliance until June 17, 2023; company plans to present plan.
Stockholders approved reverse stock split (1:2 to 1:20) in Nov 2022; CEO prefers organic growth but split is an option.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Acorda Therapeutics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

December 20, 2022, the Company received a written notice from the Staff (the “ Staff Determination ”) that that the Company’s common stock would be delisted from the Nasdaq Global Select Market and suspended at the opening of business on December 29, 2022, unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “ Panel ”). The Company intends to request a hearing before the Panel (the “ Hearing ”) to appeal the Staff Determination. This Hearing request will automatically stay Nasdaq’s delisting of the Company’s common stock pending the Panel’s decision. The Company e

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001193125-22-309544

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.